Everything about Omalizumab totally explained
Omalizumab (marketed under the name
Xolair) is a
monoclonal antibody made by
Genentech /
Novartis and used mainly in
allergy-related
asthma therapy, with the purpose of reducing allergic
hypersensitivity. Xolair (Omalizumab) is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human
immunoglobulin E (IgE). IgE is commonly involved with allergies when present in high amounts in the body.
Mechanism of action
Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor
FcεRI (and presumably to
FcεRII as well) on the surface of mast cells and basophils. Reduction in surface bound IgE on FcεRI-bearing cells limits the degree of release of mediators of the allergic response. Treatment with Xolair also reduces the number of FcεRI receptors on basophils in atopic patients.
Usage
Due to the lack of sufficient information on the long-term effectiveness and side effects of the drug,
omalizumab treatment isn't yet very common, and can be expensive. Another barrier to prevalent use is the injectable dosage form, which requires the patient to visit a physician's office or clinic every 2 to 4 weeks during treatment. Additionally, as IgE could be a natural defense against parasitic diseases, treatment is usually not recommended when living in environments where the presence of parasites is common.
Recent research suggests that
IgE might play an important role in the immune system's recognition of cancer cells, so indiscriminate blocking of
IgE /
receptor interaction might have unforeseen problems. Clinical studies have shown that patients who underwent Xolair treatment had an increased (0.5%) chance of contracting malignancies (
cancers) of various types, compared with patients who received the placebo drug (0.2%). This is considered a statistically significant increase. Concerns have also been raised about possible induction of
Churg-Strauss syndrome,
nasal polyps, and
adrenal insufficiency.
Delivery
The drug is administered
subcutaneously in 1 to 3 injections every 2 or 4 weeks. As of May 10, 2008, the company will began requiring that the drug be administered by a patients health care provider, due to a risk of
anaphylaxis. Previously, the drug was self-administered.
Further Information
Get more info on 'Omalizumab'.
|
External Link Exchanges
Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:
<a href="http://omalizumab.totallyexplained.com">Omalizumab Totally Explained</a>
Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned. |
